Does the media favor CORT or NKTR?

In the previous week, Nektar Therapeutics had 2 more articles in the media than Corcept Therapeutics. MarketBeat recorded 5 mentions for Nektar Therapeutics and 3 mentions for Corcept Therapeutics. Nektar Therapeutics' average media sentiment score of 0.69 beat Corcept Therapeutics' score of 0.63 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SUPN or NKTR?

In the previous week, Nektar Therapeutics had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 5 mentions for Nektar Therapeutics and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Nektar Therapeutics' score of 0.69 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRGO or NKTR?

In the previous week, Nektar Therapeutics had 3 more articles in the media than Perrigo. MarketBeat recorded 5 mentions for Nektar Therapeutics and 2 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.69 beat Perrigo's score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCRX or NKTR?

In the previous week, Nektar Therapeutics had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 5 mentions for Nektar Therapeutics and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Nektar Therapeutics' score of 0.69 indicating that Pacira BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacira BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NKTR or OMER more profitable?

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Nektar Therapeutics -284.18% -85.40% -39.99% Omeros N/A -102.16% 64.87%

Does the media refer more to NKTR or OMER?

In the previous week, Omeros had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 10 mentions for Omeros and 5 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.69 beat Omeros' score of -0.20 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omeros 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Nektar Therapeutics (NKTR) Competitors

$65.39 +1.74 (+2.73%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$66.01 +0.62 (+0.94%)

As of 06/29/2026 07:55 PM Eastern

Compare

NKTR vs. CORT, SUPN, PRGO, PCRX, and OMER

Should you buy Nektar Therapeutics stock or one of its competitors? MarketBeat compares Nektar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nektar Therapeutics include Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Perrigo (PRGO), Pacira BioSciences (PCRX), and Omeros (OMER). These companies are all part of the "pharmaceuticals" industry.

How does Nektar Therapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Corcept Therapeutics currently has a consensus price target of $88.83, indicating a potential upside of 1.07%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 128.82%. Given Nektar Therapeutics' higher possible upside, analysts clearly believe Nektar Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Corcept Therapeutics has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	12.39	$99.65M	$0.35	251.11
Nektar Therapeutics	$55.23M	40.01	-$164.08M	-$8.42	N/A

Corcept Therapeutics has a net margin of 6.14% compared to Nektar Therapeutics' net margin of -284.18%. Corcept Therapeutics' return on equity of 7.40% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

In the previous week, Nektar Therapeutics had 2 more articles in the media than Corcept Therapeutics. MarketBeat recorded 5 mentions for Nektar Therapeutics and 3 mentions for Corcept Therapeutics. Nektar Therapeutics' average media sentiment score of 0.69 beat Corcept Therapeutics' score of 0.63 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Summary

Corcept Therapeutics beats Nektar Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Nektar Therapeutics (NASDAQ:NKTR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Supernus Pharmaceuticals has a net margin of -3.74% compared to Nektar Therapeutics' net margin of -284.18%. Supernus Pharmaceuticals' return on equity of 13.07% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

In the previous week, Nektar Therapeutics had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 5 mentions for Nektar Therapeutics and 2 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.94 beat Nektar Therapeutics' score of 0.69 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.78	-$38.55M	-$0.51	N/A
Nektar Therapeutics	$55.23M	40.01	-$164.08M	-$8.42	N/A

Supernus Pharmaceuticals presently has a consensus target price of $62.17, indicating a potential upside of 32.83%. Nektar Therapeutics has a consensus target price of $149.63, indicating a potential upside of 128.82%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Supernus Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

75.9% of Nektar Therapeutics shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Supernus Pharmaceuticals and Nektar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Perrigo?

Perrigo (NYSE:PRGO) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Perrigo currently has a consensus price target of $19.33, suggesting a potential upside of 92.76%. Nektar Therapeutics has a consensus price target of $149.63, suggesting a potential upside of 128.82%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nektar Therapeutics has lower revenue, but higher earnings than Perrigo. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.33	-$1.43B	-$13.10	N/A
Nektar Therapeutics	$55.23M	40.01	-$164.08M	-$8.42	N/A

Perrigo has a net margin of -43.50% compared to Nektar Therapeutics' net margin of -284.18%. Perrigo's return on equity of 9.96% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-43.50%	9.96%	3.90%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

In the previous week, Nektar Therapeutics had 3 more articles in the media than Perrigo. MarketBeat recorded 5 mentions for Nektar Therapeutics and 2 mentions for Perrigo. Nektar Therapeutics' average media sentiment score of 0.69 beat Perrigo's score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Perrigo has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Summary

Nektar Therapeutics beats Perrigo on 10 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Pacira BioSciences?

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Pacira BioSciences currently has a consensus price target of $29.40, indicating a potential upside of 17.18%. Nektar Therapeutics has a consensus price target of $149.63, indicating a potential upside of 128.82%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pacira BioSciences has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

In the previous week, Nektar Therapeutics had 2 more articles in the media than Pacira BioSciences. MarketBeat recorded 5 mentions for Nektar Therapeutics and 3 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 0.96 beat Nektar Therapeutics' score of 0.69 indicating that Pacira BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacira BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 0.70% compared to Nektar Therapeutics' net margin of -284.18%. Pacira BioSciences' return on equity of 10.24% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	0.70%	10.24%	5.47%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$726.41M	1.36	$7.03M	$0.12	209.08
Nektar Therapeutics	$55.23M	40.01	-$164.08M	-$8.42	N/A

Summary

Pacira BioSciences beats Nektar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Nektar Therapeutics compare to Omeros?

Nektar Therapeutics (NASDAQ:NKTR) and Omeros (NASDAQ:OMER) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

In the previous week, Omeros had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 10 mentions for Omeros and 5 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.69 beat Omeros' score of -0.20 indicating that Nektar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omeros	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Omeros	N/A	-102.16%	64.87%

Nektar Therapeutics currently has a consensus price target of $149.63, indicating a potential upside of 128.82%. Omeros has a consensus price target of $38.00, indicating a potential upside of 283.45%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Omeros	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Omeros has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	40.01	-$164.08M	-$8.42	N/A
Omeros	$9.89M	72.50	-$3.35M	$0.70	14.16

Nektar Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Omeros has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

Summary

Omeros beats Nektar Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKTR vs. The Competition

Export

Metric	Nektar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.15B	$3.04B	$6.85B	$12.20B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-7.77	19.67	26.04	24.36
Price / Sales	40.01	338.22	550.14	102.43
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	14.83	4.25	10.98	6.49
Net Income	-$164.08M	$64.45M	$3.57B	$336.61M
7 Day Performance	-1.95%	3.73%	2.60%	1.25%
1 Month Performance	0.79%	4.01%	0.93%	0.24%
1 Year Performance	153.06%	34.35%	36.40%	30.16%

Nektar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
NKTR Nektar Therapeutics	2.8853 of 5 stars	$65.39 +2.7%	$149.63 +128.8%	+153.8%	$2.15B	$55.23M	N/A	220
CORT Corcept Therapeutics	2.538 of 5 stars	$81.56 +2.1%	$88.83 +8.9%	+20.0%	$8.76B	$761.41M	233.04	300
SUPN Supernus Pharmaceuticals	2.6929 of 5 stars	$45.40 +2.1%	$62.17 +36.9%	+50.2%	$2.64B	$718.95M	N/A	580
PRGO Perrigo	3.5462 of 5 stars	$9.77 +2.9%	$19.33 +98.0%	-62.2%	$1.35B	$4.25B	N/A	8,100
PCRX Pacira BioSciences	2.9849 of 5 stars	$23.98 +2.0%	$29.40 +22.6%	+6.9%	$943.42M	$726.41M	199.81	720

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NKTR) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CORT, SUPN, PRGO, PCRX, and OMER

How does Nektar Therapeutics compare to Corcept Therapeutics?

Summary

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Nektar Therapeutics compare to Perrigo?

Summary

How does Nektar Therapeutics compare to Pacira BioSciences?

Summary

How does Nektar Therapeutics compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nektar Therapeutics (NKTR) Competitors

NKTR vs. CORT, SUPN, PRGO, PCRX, and OMER

How does Nektar Therapeutics compare to Corcept Therapeutics?

Do insiders & institutionals have more ownership in CORT or NKTR?

Do analysts rate CORT or NKTR?

Which has better earnings & valuation, CORT or NKTR?

Is CORT or NKTR more profitable?

Does the media favor CORT or NKTR?

Which has more volatility and risk, CORT or NKTR?

Summary

How does Nektar Therapeutics compare to Supernus Pharmaceuticals?

Is SUPN or NKTR more profitable?

Does the media favor SUPN or NKTR?

Which has higher valuation & earnings, SUPN or NKTR?

Do analysts recommend SUPN or NKTR?

Which has more risk & volatility, SUPN or NKTR?

Do insiders and institutionals have more ownership in SUPN or NKTR?

Summary

How does Nektar Therapeutics compare to Perrigo?

Do analysts recommend PRGO or NKTR?

Do institutionals & insiders have more ownership in PRGO or NKTR?

Which has preferable earnings and valuation, PRGO or NKTR?

Is PRGO or NKTR more profitable?

Does the media favor PRGO or NKTR?

Which has more volatility & risk, PRGO or NKTR?

Summary

How does Nektar Therapeutics compare to Pacira BioSciences?

Do analysts rate PCRX or NKTR?

Do institutionals & insiders have more ownership in PCRX or NKTR?

Which has more risk and volatility, PCRX or NKTR?

Does the media favor PCRX or NKTR?

Is PCRX or NKTR more profitable?

Which has better earnings and valuation, PCRX or NKTR?

Summary

How does Nektar Therapeutics compare to Omeros?

Does the media refer more to NKTR or OMER?

Is NKTR or OMER more profitable?

Do analysts rate NKTR or OMER?

Do insiders and institutionals have more ownership in NKTR or OMER?

Which has preferable valuation & earnings, NKTR or OMER?

Which has more volatility & risk, NKTR or OMER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR vs. The Competition

Nektar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools